Intramuscular administration of recombinant Newcastle disease virus expressing SARS-CoV-2 spike protein protects hACE-2 TG mice against SARS-CoV-2 infection
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Deok-Hwan | - |
dc.contributor.author | Lee, Jiho | - |
dc.contributor.author | Youk, Sungsu | - |
dc.contributor.author | Jeong, Jei-Hyun | - |
dc.contributor.author | Lee, Da-Ye | - |
dc.contributor.author | Ju, Hyo-Seon | - |
dc.contributor.author | Youn, Ha-Na | - |
dc.contributor.author | Kim, Jin-Cheol | - |
dc.contributor.author | Park, Soo-Bin | - |
dc.contributor.author | Park, Ji-Eun | - |
dc.contributor.author | Kim, Ji-Yun | - |
dc.contributor.author | Kim, Tae-Hyeon | - |
dc.contributor.author | Lee, Seung-Hun | - |
dc.contributor.author | Lee, Hyukchae | - |
dc.contributor.author | Abdal, Lah Mouhamed Abdallah Amal | - |
dc.contributor.author | Lee, Dong-Hun | - |
dc.contributor.author | Park, Pil-Gu | - |
dc.contributor.author | Hong, Kee-Jong | - |
dc.contributor.author | Song, Chang-Seon | - |
dc.date.accessioned | 2023-09-02T03:40:37Z | - |
dc.date.available | 2023-09-02T03:40:37Z | - |
dc.date.created | 2023-08-29 | - |
dc.date.issued | 2023-07 | - |
dc.identifier.issn | 0264-410X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/89027 | - |
dc.description.abstract | Coronavirus disease 2019 (Covid-19) caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) became a pandemic, causing significant burden on public health worldwide. Although the timely development and production of mRNA and adenoviral vector vaccines against SARS-CoV-2 have been successful, issues still exist in vaccine platforms for wide use and production. With the potential for proliferative capability and heat stability, the Newcastle disease virus (NDV)-vectored vaccine is a highly economical and conceivable candidate for treating emerging diseases. In this study, a recombinant NDV-vectored vaccine expressing the spike (S) protein of SARS-CoV-2, rK148/beta-S, was developed and evaluated for its efficacy against SARS-CoV-2 in K18-hACE-2 transgenic mice. Intramuscular vaccination with low dose (106.0 EID50) conferred a survival rate of 76 % after lethal challenge of a SARS-CoV-2 beta (B.1.351) variant. When administered with a high dose (107.0 EID50), vaccinated mice exhibited 100 % survival rate and reduced lung viral load against both beta and delta variants (B.1.617.2). Together with the protective immunity, rK148/beta-S is an accessible and cost-effective SARS-CoV-2 vaccine. & COPY; 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.relation.isPartOf | VACCINE | - |
dc.title | Intramuscular administration of recombinant Newcastle disease virus expressing SARS-CoV-2 spike protein protects hACE-2 TG mice against SARS-CoV-2 infection | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 001047392700001 | - |
dc.identifier.doi | 10.1016/j.vaccine.2023.05.071 | - |
dc.identifier.bibliographicCitation | VACCINE, v.41, no.33, pp.4787 - 4797 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85162849339 | - |
dc.citation.endPage | 4797 | - |
dc.citation.startPage | 4787 | - |
dc.citation.title | VACCINE | - |
dc.citation.volume | 41 | - |
dc.citation.number | 33 | - |
dc.contributor.affiliatedAuthor | Park, Pil-Gu | - |
dc.contributor.affiliatedAuthor | Hong, Kee-Jong | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | SARS-CoV-2 | - |
dc.subject.keywordAuthor | Newcastle disease virus-vectored vaccine | - |
dc.subject.keywordAuthor | Intramuscular vaccine | - |
dc.subject.keywordAuthor | Lung viral load | - |
dc.subject.keywordAuthor | K18-hACE-2 TG mice | - |
dc.subject.keywordPlus | VECTOR | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.